Cellceutix Corp (OTCQB:CTIX) is based in Beverly, Massachusetts and is a clinical stage biotech company. Their product pipeline was doubled with the PolyMedix asset acquisition and now includes three drugs actively in development.
The biotechnology space has been hopping with acquisitions in 2013 as big pharma looks to refuel dwindling pipelines with new therapeutics and stave off shrinking revenue as rivals introduce generic versions of blockbuster drugs. Amgen (AMGN) shares have been on the rise since the company on August 26 said that it will spend $10.4 billion, or $125 per share, to acquire Onyx Pharmaceuticals (ONXX). The purchase is the second largest in Amgen's history, with only the $17-billion acquisition of Immunex in...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|